drugset / Trial / NCT06094777
A Study of HY-0102 in Patients With Advanced Solid Tumors
NaSequentialOpen-labelTreatment
Summary
This is a phase 1 open label multicenter study to evaluate the maximum tolerance, safety, tolerance and PK of HY-0102 administered intravenously (IV) once every two weeks in patients with advanced solid tumors, so as to confirm the recommended phase 2 dose of HY-0102 and obtain the preliminary efficacy information of patients with advanced solid tumors.
Timeline
- Start
- 2023-12-18
- Primary completion
- 2025-06
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HY-0102 | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | HY-0102 | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | HY-0102 | Monoclonal antibody | 15 mg/kg | Intravenous |